Turn Therapeutics (NASDAQ:TTRX) Raised to “Hold” at Wall Street Zen

Turn Therapeutics (NASDAQ:TTRX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Other analysts have also issued research reports about the company. Lucid Cap Mkts raised Turn Therapeutics to a “strong-buy” rating in a research note on Thursday, September 24th. WBB Securities reiterated a “sell” rating and set a $10.00 price objective on shares of Turn Therapeutics in a research note on Monday, September 14th. LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a report on Monday, July 20th. Zacks Research upgraded shares of Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings lowered shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Turn Therapeutics Price Performance

NASDAQ TTRX opened at $12.00 on Friday. Turn Therapeutics has a 1-year low of $2.57 and a 1-year high of $16.45. The company has a market capitalization of $357.48 million and a price-to-earnings ratio of -41.38. The stock’s 50 day moving average is $11.46 and its two-hundred day moving average is $7.66. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 8.83.

Turn Therapeutics (NASDAQ:TTRX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. Equities analysts forecast that Turn Therapeutics will post -0.40 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Turn Therapeutics

Several institutional investors have recently bought and sold shares of TTRX. Bank of America Corp DE acquired a new position in Turn Therapeutics in the second quarter worth $103,000. Tamar Securities LLC bought a new stake in shares of Turn Therapeutics during the fourth quarter worth $59,000. Jefferies Financial Group Inc. acquired a new stake in shares of Turn Therapeutics in the second quarter valued at $119,000. Bridgewater Advisors Inc. acquired a new stake in shares of Turn Therapeutics in the second quarter valued at $242,000. Finally, BlackRock Inc. acquired a new stake in shares of Turn Therapeutics in the second quarter valued at $282,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.